Skip to main content
Inflammation & Allergy - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in inflammation and allergy e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in inflammation and allergy. As the discovery, identification, characterization and validation of novel human drug targets for anti-inflammation and allergy drug discovery continues to grow, this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy) (Discontinued) was previously published as Current Drug Targets - Inflammation & Allergy.

Publisher: Bentham Science Publishers

More about this publication?
Volume 13, Number 4, 2014

Articles

Free Content Graphical Abstracts:
pp. i-iii(3)

Favourites:
ADD

The Gut Microbiome
pp. 217-223(7)
Author: C. Actis, Giovanni

Favourites:
ADD

ACE and ACE2 in Inflammation: A Tale of Two Enzymes
pp. 224-234(11)
Authors: Reddy Gaddam, Ravinder; Chambers, Stephen; Bhatia, Madhav

Favourites:
ADD

HSP70 Family in the Renal Inflammatory Response
pp. 235-240(6)
Author: Manucha, Walter

Favourites:
ADD

Cutaneous Adverse Drug Reactions Caused by Antituberculosis Drugs
pp. 241-248(8)
Authors: Rezakovic, Saida; Pastar, Zrinjka; Kostovic, Kresimir

Favourites:
ADD

An Update on Disease Modifying Antirheumatic Drugs
pp. 249-261(13)
Authors: Joshi, Poorvashree; S. Dhaneshwar, Suneela

Favourites:
ADD
Favourites:
ADD

Biologics for ANCA-Associated Vasculitis
pp. 275-287(13)
Authors: Murgia, Giuseppe; Firinu, Davide; E. Manconi, Paolo; R. Del Giacco, Stefano

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content